Risks of SARS-CoV-2 Breakthrough Infection and Hospitalization in Fully Vaccinated Patients With Multiple Myeloma
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
Data from early in the COVID-19 pandemic when vaccines were not available showed that patients with multiple myeloma (MM) were at increased risk for COVID-19 infection and severe outcomes.1,2 Recent studies showed a low rate of seroconversion after messenger RNA (mRNA) anti-SARS-CoV-2 vaccination in patients with MM and other hematological malignant neoplasms.3,4 However, the risk and outcomes of SARS-CoV-2 breakthrough infection in vaccinated patients with MM remains unknown.
JAMA Network Open , article en libre accès, 2020